Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07644832 SR-604 Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644832 clinical trial report covering SR-604, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07643805 EZH2i(The Institute of Cancer Research) Diffuse Large B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07643805 clinical trial report covering EZH2i(The Institute of Cancer Research), Phase 1/2, endpoints, sponsor, geography, readout timing and developmen
Latest Hotspot
8 min read
NCT07644039 Pembrolizumab Neoplasm Metastasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644039 clinical trial report covering Pembrolizumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07644403 IMC-001(Immunofoco) Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07644403 clinical trial report covering IMC-001(Immunofoco), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646210 iPSC derived cardiac muscle cell (Help Therapeutics) Heart Failure Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07646210 clinical trial report covering iPSC derived cardiac muscle cell (Help Therapeutics), Phase 1/2, endpoints, sponsor, geography, readout timing a
Latest Hotspot
8 min read
ChiCTR2600126711 Apatinib Mesylate Refractory Osteosarcoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
ChiCTR2600126711 clinical trial report covering Apatinib Mesylate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647237 GR-2301 Vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07647237 clinical trial report covering GR-2301, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07666750 EDV-01 Dysentery, Bacillary Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07666750 clinical trial report covering EDV-01, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07667387 LNP.UCD.ABE Carbamoyl-Phosphate Synthase I Deficiency Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07667387 clinical trial report covering LNP.UCD.ABE, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678307 Autologous nano CD5-CAR T cells (Institute of Hematology & Blood Diseases Hospit Precursor T-cell lymphoblastic lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07678307 clinical trial report covering Autologous nano CD5-CAR T cells (Institute of Hematology & Blood Diseases Hospit, Phase 1/2, endpoints, sponsor,
Latest Hotspot
8 min read
NCT07714317 Sintilimab Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714317 clinical trial report covering Sintilimab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07714512 Isatuximab-IRFC Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
7 August 2026
NCT07714512 clinical trial report covering Isatuximab-IRFC, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.